Morten Rühwald

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

Jaap T. van Dissel, Simone A. Joosten, Søren T. Hoff et al. · Vaccine · 2014 · 237 citations · Full text

T-regulatory Cell, Innate Immune System, Immune Regulation +17

Latent Tuberculosis in HIV positive, diagnosed by the M. Tuberculosis Specific Interferon-γ test

Inger Brock, Morten Rühwald, Bettina Lundgren et al. · Respiratory Research · 2006 · 211 citations · Full text

Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis

Morten Rühwald, Thomas Bodmer, C Maier et al. · European Respiratory Journal · 2008 · 190 citations · Full text

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang et al. · The Lancet Infectious Diseases · 2019 · 190 citations

Vaccination, Mucosal Vaccination, Caf01 Liposomes +4

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis

Albanus O. Moguche, Munyaradzi Musvosvi, Adam Penn‐Nicholson et al. · Cell Host & Microbe · 2017 · 180 citations · Full text

Pulmonary Tuberculosis, Adaptive Immune System, T-regulatory Cell +8